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Abstract
During dengue virus infection a unique cytokine, cytotoxic factor (hCF), is produced that is pathogenesis-related and plays a key role in
the development of dengue haemorrhagic fever (DHF). However, what regulates the adverse effects of hCF is not known. We have
previously shown that anti-hCF antibodies raised in mice, neutralise the pathogenic effects of hCF. In this study we have investigated the
presence and levels of hCF-autoantibodies in sera of patients with various severity of dengue illness (n = 136) and normal healthy controls
(n = 50). The highest levels of hCF-autoantibodies (mean þ S.D. = 36 þ 20 U ml31) were seen in patients with mild illness, the dengue fever
(DF), and 48 out of 50 (96%) of the sera were positive. On the other hand the hCF-autoantibody levels declined sharply with the
development of DHF and the levels were lowest in patients with DHF grade IV (mean þ S.D. = 5 þ 2 U ml31 ; P = 6 0.001 as compared to
DF). Only one of the 13 DHF grade IV patients had an antibody level above the ‘cut-off’ value (mean plus 3 S.D. of the control sera). The
analysis of data with respect to different days of illness further showed that the highest levels of hCF-autoantibodies were present in DF
patients at s 9 days of illness. Moreover, the DF patients at all time points, i.e. 1^4, 5^8 and s 9 days of illness had significantly higher
levels of hCF-autoantibodies (P6 0.001) than patients with DHF grade I, II, III and IV. In addition DHF grade I and grade II patients had
significantly more positive specimens than DHF grade III and grade IV patients at all time points. These results suggest that elevated levels
of hCF-autoantibodies protect the patients against the development of severe forms of DHF and, therefore, it may be useful as a prognostic
indicator. ß 2001 Federation of European Microbiological Societies. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
Dengue virus infection produces a mild self-limiting
acute febrile illness, dengue fever (DF), and a life-threat-
ening severe illness, dengue haemorrhagic fever (DHF)
with minor or major bleeding from di¡erent sites. The
main features of DHF are increased capillary permeability
leading to extensive plasma leakage resulting in profound
shock, increased haematocrit, thrombocytopoenia and al-
tered number and functions of leucocytes. DHF has been
classi¢ed into four grades on the basis of clinical presenta-
tion and laboratory ¢ndings; the mildest is grade I and the
most severe is grade IV [1^3]. Despite extensive studies,
the pathogenesis of DHF is still not fully understood. We
have observed that the most signi¢cant ¢ndings in patients
with severe DHF are high levels of the cytotoxic factor
(hCF) in the sera and peripheral blood leucocytes [4] and a
shift from the Th1-type response to Th2-type response [5].
During dengue virus infection the CD4 T cells produce
a unique cytokine, cytotoxic factor (CF), in mice (mCF)
and its homologue in man (hCF). The amino-terminal se-
quence of mCF has no homology with any known pro-
teins or cytokines. mCF and hCF appear to be pathogen-
esis-related proteins, capable of reproducing DHF-like
pathological lesions in mice, such as increased capillary
permeability, cerebral oedema and blood leukocyte
changes [3,6^8]. During an extensive epidemic of DHF
in Northern India during 1996, the presence of hCF was
shown in 90% of the 333 patients with peak amounts in
the most severe patients with DHF grade IV(9). Further,
ex vivo culture of peripheral blood mononuclear cells of
such patients showed the production of hCF by CD4 T
cells [4,10]. The production of mCF/hCF precedes the clin-
ical illness in mice and man [4,7^9].
We have recently proposed a mechanism to explain the
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pathogenesis of DHF in which hCF plays a key role [11].
Dengue virus replicates in macrophages and induces
quickly the CD4 T cells to produce hCF. hCF induces
macrophages to produce free radicals, nitrite, reactive oxy-
gen and peroxynitrite [12,13]. The free radicals, besides
killing the target cells by apoptosis, also directly upregu-
late production of proin£ammatory cytokines interleukin
(IL)-1K, tumour necrosis factor (TNF)-K, IL-8, and hy-
drogen peroxide in macrophages. The change in relative
levels of IL-12 and TGF-K shifts a Th1-dominant response
to a Th2-biased response resulting in an exacerbation of
dengue disease and death of patients. The vascular perme-
ability is increased due to the combined e¡ect of hista-
mine, free radicals, proin£ammatory cytokines and the
products of the complement pathway, etc. Thus, the key
player appears to be hCF, but what regulates its activity is
not known [11].
Anti-cytokine antibodies can neutralise the adverse ef-
fects of cytokines, including hCF [7], while the non-neu-
tralising type of antibodies may contribute to better tar-
geting of the cytokines to the appropriate cells [14,15].
Thus, autoantibodies may be a potent regulator of cyto-
kine functions. The present study was, therefore, under-
taken to investigate the sera of the patients with DF/DHF
for the presence of hCF-autoantibodies.
2. Materials and methods
2.1. Patients
An extensive epidemic of DHF occurred in Northern
India during August^November 1996. During this epidem-
ic serum samples were collected from the patients su¡ering
from typical dengue-like illness admitted to the Gandhi
Memorial and Associated Hospitals, Lucknow and the
Pediatrics Department of the All India Institute of Medi-
cal Sciences, New Delhi. Diagnosis of dengue virus infec-
tion was established either by virus isolation or by detec-
tion of virus-speci¢c IgM in the sera [5]. Sera were
available from a total of 136 patients for the present study.
For controls, 50 age-matched normal healthy individuals,
without history of any febrile or other illnesses in the
previous 3 months, were included. Among the patients,
50 were classi¢ed as DF, 10 as DHF grade I, 50 as grade
II, 13 as grade III and 13 as grade IV, according to the
criteria of the World Health Organisation [2]. Sera col-
lected from the patients and controls were divided in ali-
quots and quickly frozen and stored at 360‡C. For the
present study, sera were transported to Kuwait on dry ice
and stored at 370‡C until tested.
2.2. Enzyme-linked immunosorbent assay (ELISA)
The ELISA for the detection of hCF and its antibody
has been standardised and described earlier [16]. Polysty-
rene £at-bottom 96-well plates (Polysorb F96, Nunc,
Glostrup, Denmark) were used. The hCF used in the
test was puri¢ed from the sera collected from dengue pa-
tients using ion-exchange chromatography followed by
high performance liquid chromatography (HPLC) as de-
scribed [7]. The antibody against HPLC-puri¢ed hCF were
prepared in mice [7]. The anti-hCF antibody (hCFAS)
neutralises the cytotoxic activity of hCF in vitro and in-
hibits hCF-induced increase in capillary permeability in
mice and reacted speci¢cally with hCF in the Western
blot tests and ELISA. The controls included were puri¢ed
hCF as positive control and heterologous proteins as neg-
ative controls [7,8].
The sandwich ELISA was optimised by a Checkerboard
titration to ¢nd the minimum amount of hCF (on the
solid phase) that reacted with a minimum amount of
hCFAS. The antibody-binding curve indicated that a con-
centration of 300 ng ml31 hCF was optimum to coat the
solid phase. This concentration of hCF coating gave a
hCFAS binding curve with the 50% maximum binding
point at the dilution of 1:500 of hCFAS. In the test system
the recovery rates were within 10% and the variations in
the intra-assay and inter-assay were less than 10%. The
established ELISA was reproducible and the speci¢city,
sensitivity and accuracy were 92.5, 90.9 and 91%, respec-
tively [16]. To control day-to-day variations in ELISA, the
optical density (OD) values of the standard sample tested
undiluted and at 1/10, 1/100 and 1/1000 dilutions were
converted into arbitrary units and used to construct a
standard curve. Each sample was diluted 10-fold and the
test was setup in triplicate. The OD values obtained were
converted into arbitrary units ml31 (U ml31) by compar-
ison with the standard curve. The data has been presented
as U ml31 of hCFAS and analysed statistically using Stu-
dent’s t-test. A P-value of less than 0.05 was considered
signi¢cant.
3. Results
The hCF-autoantibody levels in patients with various
grades of dengue illness have been presented as mean val-
ues of the arbitrary U ml31 in Fig. 1. In patients with mild
illness, DF, the mean value of the hCF-autoantibodies was
36 þ 20 U ml31, the highest value being 109 U ml31 in one
patient. The hCF-autoantibody levels declined sharply
with the onset of DHF. In patients with DHF grade I,
grade II, grade III and grade IV the mean values were
14 þ 7, 10 þ 5, 6 þ 2.5 and 5 þ 2 U ml31 (P = 6 0.001, as
compared to DF patients). Among the 50 normal healthy
control sera the mean value for hCF-autoantibodies was
2 þ 1 U ml31 (Fig. 1). To exclude the possibility of detect-
ing non-speci¢c antibodies in the sera of the patients and
controls due to polyclonal activation of B cells, all the
samples were tested in a parallel ELISA using ovalbumin
as antigen on the solid phase. The OD values of all the
FEMSIM 1301 23-4-01
U.C. Chaturvedi et al. / FEMS Immunology and Medical Microbiology 30 (2001) 181^186182
sera in these tests were close to the OD values in the blank
wells (data not shown).
The mean value of hCF-autoantibodies in the control
sera plus 3 S.D. was considered as the ‘cut-o¡’ value. A
patient with dengue illness was considered positive if the
level of hCF-autoantibodies was more than the ‘cut-o¡’
value. The analysis of the data presented in Fig. 2 shows
that 48/50 (96%) patients with DF were positive for hCF-
autoantibodies, while 8/10 (80%) patients with DHF grade
I, 27/50 patients (54%) with DHF grade II, 2/13 patients
(15%) with DHF grade III and 1/13 patients (8%) with
DHF grade IV were positive. Thus, maximum positivity
was seen in DF patients and it decreased gradually from
less severe to more severe forms of DHF.
The hCF-autoantibody levels in di¡erent grades of
dengue disease were further analysed with respect to the
Fig. 1. Levels of hCF-autoantibodies in cases of dengue. Sera collected from the patients of various grades of the dengue illness were screened for hCF-
autoantibodies concentration by sandwich ELISA. The mean value of the data have been presented as arbitrary units (U ml31). The ¢gures in the pa-
rentheses represent the total number of patients/controls in each group.
Fig. 2. Percentage of hCF-autoantibody-positive patients as a function of the stage of dengue illness. Mean values from the 50 normal healthy control
sera plus 3 S.D. was taken as a ‘cut-o¡’ value to designate a serum sample from a patient as positive. The ¢gures in the parentheses represent total
number of the patients in each group.
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duration of illness by dividing the patients into three
groups, i.e. patients with 1^4 days, 5^8 days and s 9
days of illness. The results showed that the percentage of
positive samples in individual groups of patients on di¡er-
ent days of illness were somewhat similar (Fig. 3A). How-
ever, in DF patients, the level of hCF-autoantibodies at
s 9 days was signi¢cantly higher (P6 0.001) than the lev-
els at 1^4 and 5^8 days of illness. Moreover, DF patients
had signi¢cantly higher levels of hCF-autoantibodies
(P6 0.001) in their sera at all time points when compared
with DHF patients of grades I to IV (Fig. 3B). Similarly,
the patients with DHF grade I had signi¢cantly elevated
levels of hCF-autoantibodies in their sera on days 1^4 and
5^8 when compared with sera from DHF grade II, grade
III and grade IV (Fig. 3B).
4. Discussion
The most signi¢cant ¢nding of the present study is the
presence of hCF-autoantibodies in maximum amounts and
in a maximum number of the patients with the mild
dengue disease (DF). On the other hand, the levels of
hCF-autoantibodies and the number of sera positive for
the autoantibodies were lowest in patients with severe dis-
ease, the DHF grades III and IV. The di¡erences in the
level of autoantibodies between DF and DHF grades III
and IV were highly signi¢cant (P = 6 0.001). Thus, low
levels of the hCF-autoantibodies correlated directly with
the severity of the disease. Sera from normal healthy con-
trol individuals had minimal amounts of hCF-autoanti-
bodies and their mean value plus 3 S.D. was used as
‘cut-o¡’ value. It is noteworthy that, except for dengue,
hCF/mCF has been detected in no other infection. Fur-
ther, the amino-terminal sequence of mCF does not match
with any cytokine or known protein sequences available in
the database [3]. hCF is a cytokine produced by CD4 T
cells in response to dengue virus infection. It has been
proposed to be involved in the pathogenesis of DHF. In
general, cytokines are required for a number of normal
functions in the body but may produce pathological e¡ects
when they are present in wrong places and at wrong con-
centrations. The presence of autoantibodies to a number
of cytokines has been reported and is known to block the
activity of the cytokines [17]. Natural IgG antibodies are
found in the serum for IL-1K, IL-6, IL-10, interferon
(IFN)-K, IFN-L and GM-CSF, (reviewed in [14,15]). Small
complexes between such autoantibodies and cytokines do
not activate complement if IgG4 antibodies are involved,
and do not precipitate in vivo, but are active as in£amma-
tory complexes [17].
The anti-hCF/mCF antibodies raised in mice react spe-
Fig. 3. hCF-autoantibodies as a function of the duration and the grades of dengue illness. (A) Percentage of hCF-autoantibodies positive patients and
(B) levels of hCF-autoantibodies (U ml31) in the patients. The ¢gures above the columns represent the total number of patients in each group.
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ci¢cally with hCF/mCF in the Western blot tests and ELI-
SA, neutralise the cytotoxic activity of hCF/mCF in vitro
and inhibit hCF/mCF-induced increase in capillary perme-
ability in mice and, thus, protect mice against mCF/hCF-
induced DHF-like pathological lesions [6,7,18]. Further-
more, active vaccination of mice using mCF as antigen
protects them against subsequent challenge with mCF.
Challenge of such mice with a lethal intracerebral dose
of dengue virus fails to manifest clinical symptoms of
the disease [19]. Recently, the production of neutralising
autoantibodies has been reported by vaccination with IL-
1K [20]. Similar strategies are being successfully used in
several diseases using anti-TNF-K antibody therapy [21].
The cytokine-autoantibodies speci¢cally neutralise their
corresponding cytokines in vitro but in vivo they may
facilitate functions of cytokines in the body by acting as
speci¢c physiological carriers or in cytokine-protective or
-stabilising functions [14,15]. Therefore, it may be argued
that the hCF-autoantibodies are targeting hCF to the ap-
propriate cells and are thus consumed and have low levels
in severe disease. In another study, carried out on the
same set of sera, the levels of hCF were investigated by
inhibition ELISA [9]. The ¢ndings showed the lowest lev-
els of hCF in patients with DF and the highest in those
with DHF grade IV [9]. A comparison of the hCF [9] and
hCF-autoantibody levels in the sera, as observed in the
present study, is presented in Fig. 4. The high hCF-auto-
antibody levels in patients with DF are associated with the
low levels of hCF. On the other hand, high hCF levels in
patients with DHF grade IV are associated with low levels
of hCF-autoantibodies. Thus, a reverse correlation existed
between the two. These ¢ndings and the available data as
presented above strongly support the view that the pres-
ence of high levels of hCF-autoantibodies, that are neu-
tralising, may protect against development of severe DHF.
This is in line with the conclusions drawn with autoanti-
bodies against IL-1K in patients with chronic polyarthritis
[22].
Another interesting ¢nding that has emerged from the
present study is that the levels of the hCF-autoantibodies
may be used as an indicator of prognosis in patients with
dengue disease. If the hCF-autoantibody levels are high in
a patient, the chances are that he/she may recover without
developing DHF. However, follow-up studies, at di¡erent
time periods after the onset of clinical illness, are needed
to extend these suggestions.
Acknowledgements
We are grateful to Professor T.D. Chugh, Chairman,
Department of Microbiology, Faculty of Medicine, Ku-
wait University, Kuwait for constant help and support.
The work was supported by the Indian Council of Medical
Research, New Delhi and Kuwait University Research
Administration Grants No. MI 085, MI 108, MI 115
and MI 117.
References
[1] Agarwal, R., Kapoor, S., Nagar, R., Misra, A., Tandon, R., Mathur,
A., Misra, A.K., Srivastava, K.L. and Chaturvedi, U.C. (1999) A
clinical study of the patients with dengue haemorrhgic fever during
the epidemic of 1996 at Lucknow, India. Southeast Asian J. Trop.
Med. Publ. Health 30, 735^740.
[2] Nimmannitya, S. (1993) Clinical manifestations of dengue/dengue
Fig. 4. Comparison of the levels of hCF-autoantibodies with those of hCF (see [9]) in the sera of the patients with dengue in relation to the grades of
illness.
FEMSIM 1301 23-4-01
U.C. Chaturvedi et al. / FEMS Immunology and Medical Microbiology 30 (2001) 181^186 185
haemorrhagic fever. In: Monograph on Dengue/Dengue Haemor-
rhagic Fever (Thongcharoen, P., Ed.), vol. 22, pp. 48^54. WHO-
SEARO, New Delhi.
[3] Chaturvedi, U.C., Dhawan, R. and Mukerjee, R. (1997) Immunosup-
pression and cytotoxicity of dengue infection in the mouse model. In:
Dengue and Dengue Haemorrhagic Fever (Gubler, D.J. and Kuno,
G., Eds.), pp. 289^309. CAB International Press, Wallingford, Oxon.
[4] Agarwal, R., Chaturvedi, U.C., Misra, A., Mukerjee, R., Kapoor, S.,
Nagar, R., Tandon, R. and Mathur, A. (1998) Production of cyto-
toxic factor by peripheral blood mononuclear cells (PBMC) in pa-
tients with dengue haemorrhagic fever. Clin. Exp. Immunol. 112,
340^344.
[5] Chaturvedi, U.C., Raghupathy, R., Pacsa, A.S., Elbishbishi, E.A.,
Agarwal, R., Nagar, R., Misra, A., Kapoor, S., Mathur, A., Khan,
M.A.Y. and Azizieh, F. (1999) Shift from a Th1-type response to
Th2-type in dengue haemorrhagic fever. Curr. Sci. 76, 63^69.
[6] Chaturvedi, U.C., Dhawan, R., Khanna, M. and Mathur, A. (1991)
Breakdown of the blood^brain barrier during dengue virus infection
of mice. J. Gen. Virol. 72, 859^866.
[7] Mukerjee, R. and Chaturvedi, U.C. (1995) Cytokine antagonism by
active vaccination. Curr. Sci. 69, 901^902.
[8] Mukerjee, R., Chaturvedi, U.C., Vaughn, D.W. and Kalayanarooj, S.
(1997) Puri¢cation and pathogenicity of the cytotoxic factor from the
cases of dengue haemorrhagic fever. Curr. Sci. 72, 494^501.
[9] Chaturvedi, U.C., Agarwal, R., Misra, A., Mukerjee, R., Kapoor, S.
and Nagar, R. (1999) Cytotoxic factor in dengue haemorrhagic fever.
Med. Princ. Pract. 8, 26^31.
[10] Agarwal, R., Chaturvedi, U.C., Misra, A., Kapoor, S., Nagar, R. and
Tandon, R. (1998) CD4 positive T cells produce cytotoxic factor in
cases of dengue haemorrhagic fever. Curr. Sci. 74, 237^239.
[11] Chaturvedi, U.C., Agarwal, R., Elbishbishi, E.A. and Mustafa, A.S.
(2000) Cytokine cascade in dengue haemorrhagic fever: implications
for pathogenesis. FEMS Immunol. Med. Microbiol. 28, 183^188.
[12] Misra, A., Mukerjee, R. and Chaturvedi, U.C. (1996) Production of
nitrite by dengue virus-induced cytotoxic factor. Clin. Exp. Immunol.
104, 406^411.
[13] Misra, A., Mukerjee, R. and Chaturvedi, U.C. (1998) Respiratory
burst by dengue virus-induced cytotoxic factor. Med. Princ. Pract.
7, 251^260.
[14] Bendtzen, K. (1998) Autoantibodies to cytokines. Eur. J. Clin. Invest.
28, 300^301.
[15] Bendtzen, K., Hansen, M.B., Ross, C. and Svenson, M. (1998) High
avidity autoantobodies to cytokines. Immunol. Today 19, 209^211.
[16] Mukerjee, R. and Chaturvedi, U.C. (1997) ELISA for detection of
dengue virus induced cytokine and its antibody. Indian J. Exp. Biol.
35, 225^231.
[17] Debets, R. and Savelkoul, H.F.J. (1994) Cytokine antagonists and
their potential therapeutic use. Immunol. Today 15, 455^458.
[18] Khanna, M., Chaturvedi, U.C., Sharma, M.C., Pandey, V.C. and
Mathur, A. (1990) Increased capillary permeability mediated by a
dengue virus-induced lymphokine. Immunol. 69, 449^453.
[19] Chaturvedi, U.C., Mukerjee, R. and Dhawan, R. (1994) Active im-
munization by a dengue virus-induced cytokine. Clin. Exp. Immunol.
96, 202^207.
[20] Svenson, M., Hansen, M.B., Thomsen, A.R., Diamant, M., Nansen,
A., Rieneck, K., Otterness, I.G. and Bendtzen, K. (2000) Cytokine
vaccination: neutralizing IL-1K autoantibodies induced by immuni-
zation with homologous IL-1K. J. Immunol. Methods 236, 1^8.
[21] Isaacs, J.D., Morgan, A.W. and Strand, V. (1999) Combination bio-
logic therapy. Clin. Exp. Rheumatol. 17, S121^S124.
[22] Juovenne, P., Fossiez, F., Banchereau, J. and Miossec, P. (1997) High
levels of neutralizing autoantibodies against IL-1K are associated
with a better prognosis in chronic polyarthritis : a follow-up study.
Scand. J. Immunol. 46, 413^418.
FEMSIM 1301 23-4-01
U.C. Chaturvedi et al. / FEMS Immunology and Medical Microbiology 30 (2001) 181^186186
